The "neu Proto Oncogene Protein" is a term used in the field of molecular biology to describe a specific protein that is encoded by the mutated version of the neu proto-oncogene. This protein is commonly referred to as the neu protein or HER2/neu protein.
The neu proto-oncogene is a normal gene in the human body that functions to regulate cell growth and division. However, when this gene undergoes certain mutations, it can become an oncogene, which promotes the development and progression of cancer. The resulting neu proto oncogene protein is an altered form of the normal protein, with an overexpression or overactivity that contributes to the uncontrolled cell growth seen in cancerous cells.
The neu proto oncogene protein belongs to the human epidermal growth factor receptor (HER) family of proteins. It plays a crucial role in cell signaling pathways that regulate cell proliferation, survival, and differentiation. Overexpression or excessive activity of the neu proto oncogene protein has been linked to the development and aggressiveness of various types of cancer, including breast, ovarian, stomach, and lung cancers.
Due to its involvement in cancer growth and progression, the neu proto oncogene protein has become a significant therapeutic target for the development of novel cancer treatments. Drugs that specifically target this protein, such as trastuzumab (Herceptin), have shown promising results in reducing cancer growth and improving patient outcomes.
In summary, the neu proto oncogene protein is an altered form of a normal protein encoded by the mutated neu proto-oncogene. Its overexpression or overactivity contributes to the development and progression of certain types of cancer, making it an important target for cancer treatments.
